Brookline Capital Management Estimates SABS Q2 Earnings

SAB Biotherapeutics, Inc. (NASDAQ:SABS) – Research analysts at Brookline Capital Management issued their Q2 2025 earnings per share (EPS) estimates for SAB Biotherapeutics in a report issued on Monday, May 12th. Brookline Capital Management analyst K. Raja forecasts that the company will post earnings of ($1.10) per share for the quarter. The consensus estimate for SAB Biotherapeutics’ current full-year earnings is ($3.69) per share. Brookline Capital Management also issued estimates for SAB Biotherapeutics’ Q3 2025 earnings at ($0.43) EPS and Q4 2025 earnings at ($0.42) EPS.

A number of other research firms have also recently commented on SABS. HC Wainwright started coverage on SAB Biotherapeutics in a research report on Wednesday. They set a “buy” rating and a $10.00 target price on the stock. Chardan Capital dropped their price objective on SAB Biotherapeutics from $25.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, April 1st. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, SAB Biotherapeutics has a consensus rating of “Buy” and a consensus target price of $12.20.

SAB Biotherapeutics Stock Down 1.4%

SABS opened at $1.85 on Thursday. The company has a fifty day moving average of $1.50 and a two-hundred day moving average of $2.53. The stock has a market capitalization of $17.18 million, a price-to-earnings ratio of -0.50 and a beta of 0.47. SAB Biotherapeutics has a fifty-two week low of $1.00 and a fifty-two week high of $5.01. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.69 and a current ratio of 3.69.

SAB Biotherapeutics (NASDAQ:SABS) last posted its earnings results on Friday, May 9th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.44. SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.37%.

Institutional Trading of SAB Biotherapeutics

A number of institutional investors have recently made changes to their positions in the company. Northern Trust Corp acquired a new position in SAB Biotherapeutics in the 4th quarter valued at $43,000. Geode Capital Management LLC grew its holdings in shares of SAB Biotherapeutics by 18.8% during the fourth quarter. Geode Capital Management LLC now owns 80,234 shares of the company’s stock worth $307,000 after buying an additional 12,692 shares in the last quarter. Silver Oak Securities Incorporated acquired a new stake in shares of SAB Biotherapeutics in the first quarter valued at about $30,000. HB Wealth Management LLC raised its position in shares of SAB Biotherapeutics by 10.9% in the first quarter. HB Wealth Management LLC now owns 263,200 shares of the company’s stock valued at $358,000 after buying an additional 25,800 shares during the last quarter. Finally, Diadema Partners LP purchased a new position in shares of SAB Biotherapeutics in the fourth quarter worth about $114,000. 7.82% of the stock is owned by institutional investors and hedge funds.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.